Bone and growth safety profiles of biologic and conventional DMARDs in juvenile idiopathic arthritis: a 21-year FAERS disproportionality analysis
Inflammopharmacology · 2026-11 · 34 (11) · 7085-7099
DOI: 10.1007/s10787-026-02409-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammopharmacology, online erschienen am 06.10.2026. Verfasst von Fatih Erdem und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Faculty of Medicine, Ege University, İzmir, Turkey. fatih.erdem@ege.edu.tr. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Antirheumatic Agents, Biological Products, Bone and Bones. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Juvenile idiopathic arthritis (JIA) treatment relies on biologic and conventional disease-modifying anti-rheumatic drugs (b/csDMARDs), but pediatric-specific bone and growth safety remains incompletely characterized. Standard FAERS disproportionality analyses in pediatric polypharmacy may overstate signals through co-medication coding. We aimed to identify drug-specific bone-toxicity (Composite A) and growth/developmental (Composite B) signals and to test whether they survive a Primary-Suspect (PS) restriction designed to isolate reporter-attributed reactions. METHODS: Pre-specified disproportionality analysis of FAERS Individual Case Safety Reports (2004-2024); pediatric (≤ 17 years) JIA cohort, n = 13,459. Two parallel exposure definitions were applied: PS + SS (Primary or Secondary Suspect, broad) and PS-only (strict). Reporting odds ratios (ROR), proportional reporting ratios with χ2, IC025 and a fixed-prior Bayesian shrinkage estimate were computed; a robust signal required multi-criteria thresholds in both tracks. The PS + SS analysis was independently reproduced in Python and R, with 100% concordance in signal classification. RESULTS: Of 21 drug × composite signals under broad PS + SS analysis, only 5 met the robust-signal definition after PS-only restriction: methotrexate (both composites; bone ROR 2.4, growth ROR 3.7) and infliximab (4.3), tocilizumab (2.8), and abatacept (3.4) for bone toxicity. Etanercept and adalimumab-the two highest-exposure drugs-showed no PS-only signal despite PS + SS Composite A signals. PS + SS magnitudes attenuated by a median 87% under PS-only restriction. CONCLUSIONS: Methotrexate was the only drug with robust bone and growth signals, supporting skeletal and growth surveillance during chronic therapy; three biologics showed bone-toxicity signals. In this cohort, conventional PS + SS analysis substantially overstated signal magnitudes, supporting dual-track (PS + SS and PS-only) reporting for pediatric pharmacovigilance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Faculty of Medicine, Ege University, İzmir, Turkey. fatih.erdem@ege.edu.tr.
- Department of Pediatric Rheumatology, Faculty of Medicine, Ege University, İzmir, Turkey.
Zitieren
APA
Erdem, F., & Gürbüz, N. (2026). Bone and growth safety profiles of biologic and conventional DMARDs in juvenile idiopathic arthritis: a 21-year FAERS disproportionality analysis. Inflammopharmacology, 34(11), 7085-7099. https://doi.org/10.1007/s10787-026-02409-w
Vancouver
Erdem F, Gürbüz N. Bone and growth safety profiles of biologic and conventional DMARDs in juvenile idiopathic arthritis: a 21-year FAERS disproportionality analysis. Inflammopharmacology. 2026;34(11):7085-7099. doi:10.1007/s10787-026-02409-w
BibTeX
@article{Erdem2026,
author = {Erdem, Fatih and Gürbüz, Nida},
title = {Bone and growth safety profiles of biologic and conventional DMARDs in juvenile idiopathic arthritis: a 21-year FAERS disproportionality analysis},
journal = {Inflammopharmacology},
year = {2026},
volume = {34},
number = {11},
pages = {7085--7099},
doi = {10.1007/s10787-026-02409-w}
}
EUVIMED